Caption Management’s Kalaris Therapeutics KLRS Stock Holding History

Caption Management’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,217	Closed	-$656K	–	1625
2021 Q1	$656K	Buy	+1,217	New	+$1.02M	0.01%	762

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Caption Management's KLRS Position: Q2 2021 in Review

Caption Management sold out of Kalaris Therapeutics (KLRS) in Q2 2021, closing a stake of 1,217 shares — an estimated $656K sold.

Caption Management first reported a position in KLRS in Q1 2021 and held it in 1 quarter. The position peaked at $656K in Q1 2021. 84 funds tracked by Wall St. Rank hold KLRS as of Q2 2021.

Caption Management reported no remaining Kalaris Therapeutics position as of Q2 2021 after selling out during the quarter.
Caption Management sold 1,217 Kalaris Therapeutics shares in Q2 2021, an estimated $656K.
Caption Management first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 1 quarter.
Caption Management's Kalaris Therapeutics position peaked at $656K in Q1 2021.
84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2021.

Based on Caption Management's 13F filing for Q2 2021, filed 16 Aug 2021.